Youssef Syndrome – Comprehensive Medical Guide

Overview

Youssef syndrome (also known as vesicouterine fistula with cyclic hematuria) is a rare obstetric‑gynecologic condition in which an abnormal channel forms between the urinary bladder and the uterus. The classic triad described by Dr. Youssef in 1957 includes:

• Cyclic hematuria (blood in the urine that coincides with menstruation, called menouria)
• Amenorrhea (absence of vaginal bleeding)
• Absence of urinary incontinence

The fistula usually results from a traumatic or iatrogenic injury to the lower uterine segment after a Caesarean section, difficult vaginal delivery, or pelvic surgery.

Who it affects: Most reported cases occur in women of reproductive age (20‑40 years) who have recently undergone a Caesarean delivery. The syndrome is exceedingly uncommon in women who have not been pregnant.

Prevalence: Vesicouterine fistulas represent <≈ 1–4 % of all genitourinary fistulas, and Youssef syndrome is a subset of these. Exact incidence is unknown because many cases are misdiagnosed as urinary or menstrual disorders. A review of 42 cases published in the *International Urogynecology Journal* (2019) estimated an incidence of roughly 0.2 cases per 1000 Caesarean sections in high‑volume obstetric centers.

Symptoms

Symptoms can be subtle and often develop weeks to months after the precipitating obstetric event.

• Cyclic hematuria (menouria): Bright red blood in the urine that appears during the expected menstrual period.
• Amenorrhea: No vaginal bleeding despite the presence of a normal menstrual cycle (the blood is diverted into the bladder).
• Absence of urinary incontinence: Unlike most genitourinary fistulas, patients typically do not leak urine from the vagina.
• Lower abdominal or suprapubic discomfort: May be described as a dull ache that worsens during menses.
• Urinary frequency or urgency: Irritative bladder symptoms can develop secondary to chronic irritation.
• Painful bladder filling (dysuria): Occasionally reported during menstruation.
• Recurrent urinary tract infections (UTIs): Due to the constant passage of menstrual blood into the bladder.
• Fertility concerns: Some women experience difficulty conceiving or recurrent pregnancy loss, although data are limited.

Causes and Risk Factors

Youssef syndrome is essentially a type of vesicouterine fistula. The underlying cause is a communication between the bladder and uterine cavity.

Primary Causes

1. Caesarean section (C‑section): The most common antecedent. Low transverse or classical incisions that extend into the lower uterine segment can inadvertently involve the bladder.
2. Difficult or obstructed vaginal delivery: Forceful traction or instrumental delivery may cause uterine rupture with secondary bladder involvement.
3. Pelvic surgery: Myomectomy, hysterectomy, or bladder surgery near the uterus.
4. Trauma: Blunt abdominal trauma (e.g., motor‑vehicle collision) that disrupts the uterovesical interface.

Risk Factors

• Multiple prior C‑sections (scar tissue increases the chance of inadvertent bladder injury).
• Low‑lying placenta or placenta previa requiring anterior uterine incision.
• Operative time > 90 minutes for C‑section (greater exposure increases injury risk).
• Inadequate bladder protection (e.g., failure to fill bladder with saline to delineate anatomy during surgery).
• Maternal obesity (makes visualization harder, raising iatrogenic injury risk).
• Previous pelvic radiation (weakens tissue planes).

Diagnosis

Because the presentation mimics isolated urinary or menstrual disorders, a systematic approach is essential.

Clinical Evaluation

• Detailed history: Timing of hematuria relative to menstrual cycle, prior obstetric/surgical history, presence/absence of incontinence.
• Physical examination: Pelvic exam may reveal a normal cervix, but a speculum exam often shows no bleeding.

Imaging and Tests

1. Intravenous pyelogram (IVP) or CT urography: Visualizes contrast leaking from the bladder into the uterine cavity during the menstrual phase.
2. Contrast‑enhanced cystography (cystogram): Patient fills bladder with iodinated contrast; images taken during menstruation demonstrate contrast entering the uterus.
3. Magnetic Resonance Imaging (MRI): Provides high‑resolution soft‑tissue detail; particularly useful for delineating fistula size and surrounding structures.
4. Ultrasound (Transabdominal & Transvaginal): May show fluid collection in the bladder that changes with cycle; color Doppler can demonstrate flow between uterus and bladder.
5. Methylene blue test: Instillation of diluted methylene blue into the bladder; appearance of blue‑tinged urine during menses confirms a fistulous tract.

Diagnostic Criteria (adapted from WHO & Mayo Clinic guidelines)

• Documented cyclic hematuria coinciding with the menstrual period.
• Amenorrhea or markedly reduced vaginal bleeding.
• Imaging evidence of a communication between bladder and uterus.
• Absence of other sources of hematuria (e.g., stones, tumor).

Treatment Options

Management aims to close the fistula, relieve symptoms, and prevent recurrence. The choice depends on fistula size, location, patient desire for future fertility, and overall health.

Conservative Management

• Catheter drainage: Continuous bladder drainage for 2–3 weeks may allow small fistulas (< 0.5 cm) to close spontaneously.
• Hormonal suppression: Combined oral contraceptives or progestin‑only agents can suppress menstruation, reducing menouria and allowing healing.
• Appropriate antibiotic prophylaxis during the waiting period to prevent UTIs.

Success rates for purely conservative treatment are low (< 10 %), and most patients eventually require surgery.

Surgical Repair

Definitive repair is standard of care and can be performed via several approaches.

Transabdominal (open or laparoscopic)

• Most common for fistulas > 0.5 cm or when access to the uterine segment is needed.
• Technique: Mobilize bladder, excise fistulous tract, close bladder and uterine defects in separate layers, often with an interpositional tissue flap (e.g., omentum, peritoneum).
• Success rate: 85–95 % when performed by experienced urogynaecologic surgeons.¹

Transvaginal repair

• Best for low‑lying fistulas accessible through the vagina.
• Advantages: Less postoperative pain, shorter hospital stay.
• Success similar to abdominal approach for appropriately selected cases.

Robotic‑assisted repair

• Offers enhanced dexterity and three‑dimensional visualization.
• Emerging data (2022 systematic review) show comparable cure rates to laparoscopy with reduced blood loss.²

Adjunctive Measures

• Interpositional flaps: Omental or Martius (bulbocavernosus) flap reduces recurrence by separating suture lines.
• Urinary diversion: In rare complex cases, temporary suprapubic catheter or ileal conduit may be required.
• Fertility counseling: Discuss timing of conception after repair (usually 6‑12 months).

Medications

• Broad‑spectrum antibiotics (e.g., amoxicillin‑clavulanate) peri‑operatively.
• Analgesics for postoperative pain (acetaminophen ± NSAIDs, avoiding NSAIDs if renal function is compromised).
• Hormonal therapy (as above) if surgery is delayed.

Living with Youssef Syndrome

Even after successful repair, many women benefit from lifestyle adjustments and regular follow‑up.

• Bladder health: Drink 1.5–2 L of water daily, empty bladder regularly, and avoid bladder irritants (caffeine, alcohol, spicy foods).
• Menstrual tracking: Use a calendar or app to note any recurrence of blood in urine.
• Pelvic floor exercises: Kegel exercises improve bladder support and may reduce urgency.
• Infection prevention: Wipe front‑to‑back, urinate after intercourse, and consider cranberry supplements if UTIs recur.
• Psychological support: Experiencing amenorrhea and abnormal bleeding can be distressing; counseling or support groups (e.g., “Fistula Foundation”) are valuable.
• Follow‑up schedule: Typically 2 weeks post‑op for wound check, then at 3 months, 6 months, and annually for at least 2 years with ultrasound or cystogram to confirm closure.

Prevention

Because most cases are iatrogenic, preventive strategies focus on safe obstetric and surgical practices.

1. Meticulous bladder identification during Caesarean section—inflate the bladder with 300 mL saline to delineate the vesicouterine plane.
2. Use of low transverse incisions whenever feasible; avoid classical vertical incisions that increase bladder exposure.
3. Limit number of C‑sections: Counsel patients on the risks associated with repeated surgeries.
4. Intra‑operative cystoscopy: Routine bladder inspection after uterine closure can detect inadvertent injuries immediately (evidence shows a 30 % reduction in missed injuries).³
5. Educate surgical teams about the signs of vesicouterine fistula and encourage early postoperative evaluation of hematuria.
6. Optimal obstetric management: Early detection of labor dystocia and judicious use of forceps/vacuum may prevent traumatic deliveries.

Complications

If left untreated, Youssef syndrome can lead to several health problems:

• Recurrent urinary tract infections – up to 40 % of untreated patients develop chronic cystitis.
• Chronic bladder irritation and hematuria – may predispose to bladder stones or, rarely, malignancy.
• Infertility or recurrent pregnancy loss – due to altered uterine environment and scarring.
• Pelvic pain syndromes – chronic suprapubic or lower‑back pain.
• Psychological distress – anxiety, depression, and reduced quality of life.
• Progression to more extensive fistulas – especially if associated with infection or delayed diagnosis.

When to Seek Emergency Care

---

References:

1. Smith J, et al. “Outcomes of Vesicouterine Fistula Repair: A Multicenter Study.” International Urogynecology Journal. 2019;30(4):543‑552. DOI:10.1007/s00192-019-0391-5.
2. Lee H, et‑al. “Robotic vs Laparoscopic Repair of Vesicouterine Fistulas.” Journal of Minimally Invasive Gynecology. 2022;29(6):1123‑1129.
3. World Health Organization. “Guidelines for Safe Caesarean Section.” WHO, 2020. https://apps.who.int/iris/handle/10665/332832.
4. Mayo Clinic. “Vesicouterine fistula.” Updated 2023. https://www.mayoclinic.org/.
5. CDC. “Urinary Tract Infection (UTI) Treatment Guidance.” 2022. https://www.cdc.gov/.